SEC Form SC 13G filed by Harvard Bioscience Inc.

8/28/23 3:07:19 PM ET

Biotechnology: Laboratory Analytical Instruments

Industrials

Get the next $HBIO alert in real time by email

SC 13G 1 hbio13g.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* HARVARD BIOSCIENCE INC -------------------------------------------------------------------- (Name of Issuer) Common Stock ------------------------------------------------------------------ (Title of Class of Securities) 416906105 ---------------------------------------------------------------------- (CUSIP Number) 08/25/2023 ---------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: /X/ Rule 13d-i(b) / / Rule 13d-i(c) / / Rule 13d-i(d) ------------------------ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP NO. 416906105 13G ------------------------------------------------------------------------ -------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) AMH Equity LLC ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 119,466 BENEFICIALLY -------------------------------------------------- OWNED BY 6 SHARED VOTING POWER EACH ------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 119,466 WITH ------------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,158,794 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.06% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* PN ------------------------------------------------------------------------ CUSIP NO. 416906105 13G ------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Leviticus Partners, L.P. ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 2,039,328 Shares of Common Stock BENEFICIALLY ------------------------------------------ OWNED BY 6 SHARED VOTING POWER EACH ----------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 2,039,328 Shares of Common Stock WITH --------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,158,794 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.06% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IA ------------------------------------------------------------------------ ITEM 1: (a) NAME OF ISSUER: HARVARD BIOSCIENCE INC (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 84 October Hill Road Holliston MA 01746 ITEM 2: (a) NAME OF PERSON FILING: This Schedule 13G is jointly filed by Leviticus Partners, L.P., a Delaware limited partnership ("Leviticus"), and AMH Equity, LLC ("AMH"), a New York limited liability company (each a "Reporting Person" and, collectively, the "Reporting Persons"). AMH is the general partner of Leviticus. (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE : 32 Old Mill Road Great Neck, NY 11023 (c) CITIZENSHIP: See above (d) TITLE OF CLASS OF SECURITIES: SEE COVER PAGE (e) CUSIP NUMBER: SEE COVER PAGE ITEM 3: See Item 12 above ITEM 4: (a) AMOUNT BENEFICIALLY OWNED: See Item 9 above (b) PERCENT OF CLASS: See Item 11 above (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS VOTING AND DISPOSITIVE POWERS: See Items 5 and 7 above ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: / / ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: N/A The principal address of Leviticus is: 32 Old Mill Road Great Neck, NY 11023 ITEM 7: Inapplicable ITEM 8: Inapplicable ITEM 9: NOTICE OF DISSOLUTION OF GROUP: Inapplicable ITEM 10: CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in theordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: August 28, 2023 Leviticus Partners, L.P. By: AMH Equity, LLC, its general partner By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member AMH Equity, LLC By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member

Get the next $HBIO alert in real time by email

Date

Price Target

Rating

Analyst

3/10/2023

$3.00 → $4.00

Speculative Buy → Buy

The Benchmark Company

SEC Form SC 13G filed by Harvard Bioscience Inc.

Chat with this insight

Recent Analyst Ratings for $HBIO

$HBIO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

Loy Bertrand was granted 56,575 shares (SEC Form 4)

$HBIO Press Releases

Fastest customizable press release news feed in the world

Harvard Bioscience Announces Third Quarter 2024 Financial Results

Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024

$HBIO Leadership Updates

Live Leadership Updates

$HBIO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$HBIO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$HBIO Large Ownership Changes

This live feed shows all institutional transactions in real time.

$HBIO SEC Filings

Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer

Harvard Biosci upgraded by The Benchmark Company with a new price target

KeyCorp reiterated coverage on Harvard Bioscience with a new price target

Chief Executive Officer Green James W bought $29,100 worth of shares (10,000 units at $2.91), increasing direct ownership by 0.32% to 3,111,091 units (SEC Form 4)

Green James W bought $61,400 worth of shares (20,000 units at $3.07), increasing direct ownership by 0.65% to 3,101,091 units (SEC Form 4)

Amendment: SEC Form SC 13G/A filed by Harvard Bioscience Inc.